Relay Therapeutics logo
Relay Therapeutics RLAY
$ 10.06 1.46%

Quarterly report 2025-Q3
added 11-06-2025

report update icon

Relay Therapeutics Financial Statements 2011-2026 | RLAY

Annual Financial Statements Relay Therapeutics

2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

534 M 1.31 B 1.94 B 2.92 B 1.77 B - - - - - - - - -

Shares

143 M 123 M 112 M 95.1 M 42.6 M - - - - - - - - -

Historical Prices

3.74 10.7 17.3 30.7 41.6 - - - - - - - - -

Net Income

-338 M -342 M -291 M -364 M -52.4 M -75.3 M -48.8 M - - - - - - -

Revenue

10 M 25.5 M 1.38 M 3.03 M 82.7 M - - - - - - - - -

Operating Income

-372 M -373 M -299 M -365 M -55.8 M -84 M - - - - - - - -

Interest Expense

34.8 M 31 M 8.77 M 826 K 3.38 M 8.74 M - - - - - - - -

EBITDA

-367 M -368 M -295 M -361 M -52.2 M -81.2 M -47.7 M - - - - - - -

Operating Expenses

382 M 399 M 301 M 368 M 138 M 84 M 49.9 M - - - - - - -

General and Administrative Expenses

76.6 M 75 M 66 M 57.4 M 38.6 M 13.7 M 8.86 M - - - - - - -

All numbers in USD currency

Quarterly Income Statement Relay Therapeutics

2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

172 M 171 M 169 M 168 M 140 M 133 M 131 M 127 M 122 M 122 M 121 M 121 M 111 M 109 M 108 M 108 M 92.7 M 91.9 M 90.2 M 89.9 M 71.2 M 4.41 M 4.15 M 4.04 M 3.56 M 3.32 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Net Income

-74.1 M -70.4 M -77.1 M - -88.1 M -92.2 M -81.4 M - -65.7 M -98.5 M -94.2 M - -84.2 M -76.8 M -62 M - -60.8 M -193 M -42.2 M - -36.1 M -26.7 M -24.9 M - -19.7 M -17.5 M -14.2 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Revenue

- 677 K 7.68 M - - - 10 M - 25.2 M 119 K 226 K - 344 K 365 K 419 K - 666 K 844 K 952 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Income

-80.4 M -76.8 M -84.9 M - -96.4 M -101 M -90.4 M - -73.6 M -106 M -101 M - -85.9 M -77.8 M -62.7 M - -61 M -194 M -42.4 M - -36.6 M -27.7 M -26.5 M - -21.9 M -19.9 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Interest Expense

6.24 M 6.47 M 7.8 M - 8.26 M 8.54 M 8.98 M - 7.84 M 7.54 M 6.94 M - 1.72 M 1.02 M 675 K - 157 K 181 K 221 K - 529 K 995 K 1.57 M - 2.24 M 2.37 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

EBITDA

- - -83.7 M - - - -89 M - - - -100 M - -82.9 M -77.8 M -61.7 M - -58.1 M -194 M -41.5 M - -34 M -26 M -25.6 M - -19.9 M -18.5 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Expenses

80.4 M 77.5 M 92.5 M - 96.4 M 101 M 100 M - 98.8 M 106 M 101 M - 86.2 M 78.2 M 63.1 M - 61.7 M 194 M 43.4 M - 36.6 M 27.7 M 26.5 M - 21.9 M 19.9 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

General and Administrative Expenses

12.1 M 13.6 M 18.7 M - 19.8 M 20.1 M 19.8 M - 18.5 M 20.1 M 19.6 M - 16.1 M 17.5 M 16.1 M - 14.7 M 14.4 M 12.7 M - 12.2 M 6.05 M 4.76 M - 3.65 M 3.51 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Financial statements are the primary tool companies use to inform stakeholders about their financial position, performance, and changes in capital structure. It is a kind of "business language" understood by investors, creditors, tax authorities, and other participants in the economic environment.

Main types of financial statements Relay Therapeutics RLAY
  1. Income Statement
    Shows income, expenses, and resulting profit or loss over a specific period. Helps assess business profitability.
  2. Balance Sheet
    Reflects a company’s assets, liabilities, and equity as of a specific date. It’s a snapshot of what the company owns and owes.
    Assets — everything the company owns (cash, equipment, buildings, accounts receivable, etc.).
    Liabilities — debts and other external sources of financing.
    Equity — owners' capital and retained earnings.
  3. Cash Flow Statement
    Reveals how the company earns and spends money in three areas: operating, investing, and financing activities.
International reporting standards
  • IFRS — International Financial Reporting Standards, applicable to public and multinational companies.
  • GAAP — Generally Accepted Accounting Principles used in the United States.
  • RAS — Russian Accounting Standards, used domestically in Russia.

Financial reporting Relay Therapeutics plays a crucial role for investors as it serves as an objective source of information about a company's current state. Based on the reports, one can determine whether a company is growing, stagnating, or losing market share. This allows investors to identify both promising and problematic assets in a timely manner.

In addition, financial data provides a basis for forecasting future returns. Historical trends in revenue, profit, and cash flow help evaluate potential dividends, the likelihood of stock price growth, and overall investment risk.

Transparent and accurate reporting is also an indicator of a company’s maturity and managerial responsibility. Such openness builds investor confidence and simplifies investment decision-making, especially when comparing multiple companies.

Finally, financial statements enable high-quality comparative analysis. They allow companies to be evaluated against each other in terms of profitability, debt levels, margins, and other key metrics — which is particularly important when choosing the best investment options within an industry or market segment.

Financial statements of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
Grifols, S.A. Grifols, S.A.
GRFS
$ 7.68 - $ 6.83 B spainSpain
Altimmune Altimmune
ALT
$ 3.47 3.74 % $ 306 M usaUSA
Amgen Amgen
AMGN
- - $ 188 B usaUSA
Amphastar Pharmaceuticals Amphastar Pharmaceuticals
AMPH
- - $ 915 M usaUSA
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
Genfit SA Genfit SA
GNFT
- 2.54 % $ 160 B franceFrance
Heron Therapeutics Heron Therapeutics
HRTX
- - $ 130 M usaUSA
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
Ascendis Pharma A/S Ascendis Pharma A/S
ASND
$ 218.0 -1.75 % $ 5 B danmarkDanmark
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
- - $ 26.5 M usaUSA
ARCA biopharma ARCA biopharma
ABIO
- 1052.0 % $ 415 M usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
Acorda Therapeutics Acorda Therapeutics
ACOR
- -24.86 % $ 820 K usaUSA
Albireo Pharma Albireo Pharma
ALBO
- -0.23 % $ 916 M usaUSA
Aileron Therapeutics Aileron Therapeutics
ALRN
- 10.36 % $ 9.8 M usaUSA
Acasti Pharma Acasti Pharma
ACST
- 4.01 % $ 150 M canadaCanada
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
- - - russiaRussia
Incyte Corporation Incyte Corporation
INCY
$ 90.75 -0.03 % $ 17.7 B usaUSA
Inovio Pharmaceuticals Inovio Pharmaceuticals
INO
$ 1.57 -0.63 % $ 34.8 M usaUSA
Avenue Therapeutics Avenue Therapeutics
ATXI
- -52.27 % $ 4.45 M usaUSA
Adverum Biotechnologies Adverum Biotechnologies
ADVM
- - $ 86.2 M usaUSA
Acer Therapeutics Acer Therapeutics
ACER
- 2.71 % $ 14 M usaUSA
Advaxis Advaxis
ADXS
- -9.65 % $ 45.9 M usaUSA
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
- - $ 7.46 M israelIsrael
Cullinan Management Cullinan Management
CGEM
$ 12.91 1.33 % $ 778 M usaUSA
Atreca Atreca
BCEL
- -11.76 % $ 5.79 M usaUSA
BioDelivery Sciences International BioDelivery Sciences International
BDSI
- -4.8 % $ 255 M usaUSA
BeiGene, Ltd. BeiGene, Ltd.
BGNE
- 0.49 % $ 251 B cayman-islandsCayman-islands
Inventiva S.A. Inventiva S.A.
IVA
$ 6.11 5.71 % $ 138 M franceFrance
Calithera Biosciences Calithera Biosciences
CALA
- -10.95 % $ 876 K usaUSA
Cara Therapeutics Cara Therapeutics
CARA
- -3.03 % $ 260 M usaUSA
ChemoCentryx ChemoCentryx
CCXI
- - $ 3.74 B usaUSA
Bellerophon Therapeutics Bellerophon Therapeutics
BLPH
- -74.18 % $ 955 K usaUSA
Checkpoint Therapeutics Checkpoint Therapeutics
CKPT
- - $ 169 M usaUSA
Clovis Oncology Clovis Oncology
CLVS
- -7.23 % $ 13 M usaUSA
KalVista Pharmaceuticals KalVista Pharmaceuticals
KALV
$ 16.73 -1.59 % $ 831 M britainBritain
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
CureVac N.V. CureVac N.V.
CVAC
- - $ 867 M germanyGermany
Denali Therapeutics Denali Therapeutics
DNLI
$ 21.04 4.31 % $ 3.46 B usaUSA
Kamada Ltd. Kamada Ltd.
KMDA
$ 8.27 0.24 % $ 260 M israelIsrael
Karyopharm Therapeutics Karyopharm Therapeutics
KPTI
$ 6.93 -9.17 % $ 845 K usaUSA
Keros Therapeutics Keros Therapeutics
KROS
$ 11.17 1.92 % $ 416 M usaUSA
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
Arbutus Biopharma Corporation Arbutus Biopharma Corporation
ABUS
$ 4.3 1.37 % $ 714 M canadaCanada
Akouos Akouos
AKUS
- 0.23 % $ 488 M usaUSA